Esperion Therapeutics Inc (ESPR)vsNovartis AG ADR (NVS)
ESPR
Esperion Therapeutics Inc
$3.18
0.00%
HEALTHCARE · Cap: $819.47M
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 13455% more annual revenue ($56.69B vs $418.24M). NVS leads profitability with a 22.5% profit margin vs -1.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ESPR
Avoid34
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ESPR.
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 23.2% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -260.8% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ESPR
The strongest argument for ESPR centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : ESPR
The primary concerns for ESPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ESPR profiles as a growth stock while NVS is a value play — different risk/reward profiles.
ESPR carries more volatility with a beta of 1.06 — expect wider price swings.
ESPR is growing revenue faster at 23.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Esperion Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?